Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes.

"Duality of Interest. J.C.N.C. has received research grants and/or honoraria for consultancy and/or lectures from AstraZeneca, Bayer, Boehringer Ingelheim, Celltrion, Eli Lilly, Hua Medicine, Lee Powder, Merck Serono, Merck Sharp & Dohme, Pfizer, Servier, Sanofi, and Viatris; holds patents for using biomarkers to predict risks of diabetes and its complications; and is a cofounder of GemVCare, a biotechnology company partially supported by the Hong Kong Government startup fund. E.C. has received research grants and/or honoraria for lectures from Sanofi, Lee Powder, Medtronic Diabetes, and Novartis. A.M. has received financial support from Eli Lilly and is a consultant for Eli Lilly. C.K.P.L. and R.C.W.M. are cofounders of GemVCare, a technology startup initiated with support from the Hong Kong Government Innovation and Technology Commission and its Technology Start-up Support Scheme for Universities. L.C. is an affiliate of Hua Medicine. No other potential conflicts of interest relevant to this article were reported."

"Funding. This study was supported by a Hua Medicine Investigator Initiated Study (to J.C.N.C.) and The Chinese University of Hong Kong Direct Grant for Research (2020.231) (to E.C.). R.C.W.M. acknowledges support from the RGC Research Impact Fund (R4012-18) and a Croucher Foundation Senior Medical Research Fellowship."